Evidence map›Paper›PMID 33467877›Full record

Trial reportStroke2021

Diffusion-Weighted Imaging Lesions After Intracerebral Hemorrhage and Risk of Stroke: A MISTIE III and ATACH-2 Analysis.

Santosh B Murthy, Cenai Zhang, Ajay Gupta, Sung-Min Cho, Lucia Rivera-Lara, Radhika Avadhani, Joshua Gruber, Costantino Iadecola, Guido J Falcone, Kevin N Sheth and 5 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Stroke, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Santosh B MurthyClinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology (S.B.M., C.Z., C.I., H.K.), Weill Cornell Medicine, New York, NY.
Cenai ZhangClinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology (S.B.M., C.Z., C.I., H.K.), Weill Cornell Medicine, New York, NY.
Ajay GuptaDepartment of Radiology (A.G.), Weill Cornell Medicine, New York, NY.
Sung-Min ChoDivision of Neurosciences Critical Care, Johns Hopkins University School of Medicine, Baltimore, MD (S.-M.C., L.R.-L., W.C.Z.).
Lucia Rivera-LaraDivision of Neurosciences Critical Care, Johns Hopkins University School of Medicine, Baltimore, MD (S.-M.C., L.R.-L., W.C.Z.).
Radhika AvadhaniBrain Injury Outcomes Center, Johns Hopkins University, Baltimore, MD (R.A., J.G., D.F.H.).
Joshua GruberBrain Injury Outcomes Center, Johns Hopkins University, Baltimore, MD (R.A., J.G., D.F.H.).
Costantino IadecolaClinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology (S.B.M., C.Z., C.I., H.K.), Weill Cornell Medicine, New York, NY.
Guido J FalconeDivision of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, CT (G.J.F., K.N.S.).
Kevin N ShethDivision of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, CT (G.J.F., K.N.S.).
Adnan I QureshiZeenat Qureshi Stroke Institutes and Department of Neurology, University of Missouri, Columbia (A.I.Q.).
Joshua N GoldsteinDepartment of Emergency Medicine, Massachusetts General Hospital, Boston (J.N.G.).
Daniel F HanleyBrain Injury Outcomes Center, Johns Hopkins University, Baltimore, MD (R.A., J.G., D.F.H.).
Hooman KamelClinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology (S.B.M., C.Z., C.I., H.K.), Weill Cornell Medicine, New York, NY.
Wendy C ZiaiDivision of Neurosciences Critical Care, Johns Hopkins University School of Medicine, Baltimore, MD (S.-M.C., L.R.-L., W.C.Z.).
Johns Hopkins University · USCornell University · USYale University · USCentraCare Health System · USMassachusetts General Hospital · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Albert C Shaw · 2002 to 2026
$37.9M
Johns Hopkins-Tufts Trial Innovation Center HEAL Pain ERN SupplementU24TR001609 · NCATS · JOHNS HOPKINS UNIVERSITY · PI HANLEY, DANIEL F · 2016 to 2022
$36.3M
MISTIE III_ Lead Grant_ Cluster Application for the Clinical Coordinating CenterU01NS080824 · NINDS · JOHNS HOPKINS UNIVERSITY · PI HANLEY, DANIEL F · 2013 to 2017
$23.2M
AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenicstroke (ARCADIA)U01NS095869 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRODERICK, JOSEPH PAUL, KAMEL, HOOMAN · 2017 to 2022
$22.0M
Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)U01NS106513 · NINDS · YALE UNIVERSITY · PI Hooman Kamel, Kevin Navin Sheth · 2019 to 2026
$20.6M
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II)U01NS062091 · NINDS · UNIVERSITY OF MINNESOTA · PI QURESHI, ADNAN IQBAL · 2010 to 2014
$18.1M
The Recovery in Stroke Using PAP (RISE UP) StudyR01NR018335 · NINR · YALE UNIVERSITY · PI REDEKER, NANCY S, SHETH, KEVIN NAVIN · 2019 to 2023
$3.4M
Southern New England Partnership In Stroke Research, Innovation and Treatment (SPIRIT)U24NS107215 · NINDS · YALE UNIVERSITY · PI MARK Jay ALBERTS, Karen L Furie · 2018 to 2026
$3.0M
SCORE-IT: The CTA Spot Sign Score in Acute Cerebral HemorrhageR01NS073344 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI ROSAND, JONATHAN · 2011 to 2015
$2.2M
Microglia/macrophage polarization after intracerebral hemorrhageR01NS102583 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KOEHLER, RAYMOND CHARLES · 2018 to 2021
$1.8M
Yale Clinical Site: Investigations For Improved Neurological Treatments at Yale (INFINITY)U24NS107136 · NINDS · YALE UNIVERSITY · PI SHETH, KEVIN NAVIN, SPUDICH, SERENA S · 2018 to 2022
$1.7M
NCATS NIH HHS U24 TR001609NCATS NIH HHS UL1 TR001863NIA NIH HHS K76 AG059992NIA NIH HHS P30 AG021342NINDS NIH HHS K23 NS105948NINDS NIH HHS R01 NS073344NINDS NIH HHS R01 NS102583NINDS NIH HHS R03 NS112859NINDS NIH HHS U01 NS062091NINDS NIH HHS U01 NS080824NINDS NIH HHS U01 NS095869NINDS NIH HHS U01 NS106513NINDS NIH HHS U24 NS107136NINDS NIH HHS U24 NS107215NINR NIH HHS R01 NR018335
6 · The paper itself

Abstract

background and purposePunctate ischemic lesions noted on diffusion-weighted imaging (DWI) are associated with poor functional outcomes after intracerebral hemorrhage (ICH). Whether these lesions increase long-term risk of stroke is poorly understood.

methodsWe pooled individual patient data from the ATACH-2 trial (Antihypertensive Treatment of Acute Cerebral Hemorrhage) and the MISTIE III trial (Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation Phase 3). We included subjects with a magnetic resonance imaging scan. The exposure was a DWI lesion. The primary outcome was any stroke, defined as a composite of ischemic stroke or recurrent ICH, whereas secondary outcomes were incident ischemic stroke and recurrent ICH. Using multivariate Cox regression analysis, we evaluated the risk of stroke.

resultsOf 505 patients with ICH with magnetic resonance imaging, 466 were included. DWI lesions were noted in 214 (45.9%) subjects, and 34 incident strokes (20 ischemic stroke and 14 recurrent ICH) were observed during a median follow-up of 324 days (interquartile range, 91-374). Presence of a DWI lesion was associated with a 6.9% (95% CI, 2.2-11.6) absolute increase in risk of all stroke (hazard ratio, 2.6 [95% CI, 1.2-5.7]). Covariate adjustment with Cox regression models also demonstrated this increased risk. In the secondary analyses, there was an increased risk of ischemic stroke (hazard ratio, 3.5 [95% CI, 1.1-11.0]) but not recurrent ICH (hazard ratio, 1.7 [95% CI, 0.6-5.1]).

conclusionsIn a heterogeneous cohort of patients with ICH, presence of a DWI lesion was associated with a 2.5-fold heightened risk of stroke among ICH survivors. This elevated risk persisted for ischemic stroke but not for recurrent ICH.

Indexed as

AdultAgedAged, 80 and overAntihypertensive AgentsCerebral HemorrhageCohort StudiesDiffusion Magnetic Resonance ImagingFemaleFollow-Up StudiesHumansHypertensionIschemic StrokeMaleMiddle AgedNeurosurgical ProceduresRecurrenceAntihypertensive Agentscerebral hemorrhagehematomahypertensionmagnetic resonance imagingrisk

Identifiers

PMID33467877
PMCPMC8340082
OpenAlexW3123717528

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.